Insulet's Stock Slide: Is Growth Story Over?
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Insulets stock has plummeted 33.8% in six months, trading at $204.57, due to weaker prices. However, the companys constant currency revenue has grown by 25.9% year-over-year over the last two years, indicating steady demand for their Omnipod insulin delivery system. Free cash flow margins have surged by 30.1 percentage points over five years, reaching 13.7% in the trailing twelve months, and return on invested capital continues to rise. Despite the stocks current valuation at 32.7 times forward earnings, investors are buzzing about the potential for Insulets growth story to continue.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/cdf91714a5ba19f1